CA2742474C - Method for the production of adenoviral vectors - Google Patents
Method for the production of adenoviral vectors Download PDFInfo
- Publication number
- CA2742474C CA2742474C CA2742474A CA2742474A CA2742474C CA 2742474 C CA2742474 C CA 2742474C CA 2742474 A CA2742474 A CA 2742474A CA 2742474 A CA2742474 A CA 2742474A CA 2742474 C CA2742474 C CA 2742474C
- Authority
- CA
- Canada
- Prior art keywords
- cells
- cell
- rad35
- adenovirus
- bioreactor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 95
- 238000004519 manufacturing process Methods 0.000 title claims description 55
- 239000013598 vector Substances 0.000 title description 46
- 208000015181 infectious disease Diseases 0.000 claims abstract description 103
- 241000701161 unidentified adenovirus Species 0.000 claims abstract description 97
- 230000010412 perfusion Effects 0.000 claims abstract description 82
- 241000700605 Viruses Species 0.000 claims description 66
- 239000002245 particle Substances 0.000 claims description 48
- 238000003306 harvesting Methods 0.000 claims description 25
- 238000012258 culturing Methods 0.000 claims description 22
- 230000002458 infectious effect Effects 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 241000701124 Human adenovirus 35 Species 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 399
- 230000008569 process Effects 0.000 description 42
- 238000004128 high performance liquid chromatography Methods 0.000 description 23
- 239000002609 medium Substances 0.000 description 22
- 238000000746 purification Methods 0.000 description 21
- 238000011534 incubation Methods 0.000 description 20
- 229960005486 vaccine Drugs 0.000 description 20
- 230000000644 propagated effect Effects 0.000 description 17
- 239000001963 growth medium Substances 0.000 description 15
- 238000005571 anion exchange chromatography Methods 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 241001135569 Human adenovirus 5 Species 0.000 description 12
- 238000005119 centrifugation Methods 0.000 description 12
- 239000012510 hollow fiber Substances 0.000 description 12
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 11
- 230000002950 deficient Effects 0.000 description 11
- 239000012737 fresh medium Substances 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 101100113692 Caenorhabditis elegans clk-2 gene Proteins 0.000 description 9
- 239000003599 detergent Substances 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 230000035899 viability Effects 0.000 description 9
- 229930006000 Sucrose Natural products 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 229920004890 Triton X-100 Polymers 0.000 description 8
- 239000013504 Triton X-100 Substances 0.000 description 8
- 238000013019 agitation Methods 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000004017 serum-free culture medium Substances 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 101710163270 Nuclease Proteins 0.000 description 6
- 238000005349 anion exchange Methods 0.000 description 6
- 230000006037 cell lysis Effects 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108700039887 Essential Genes Proteins 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 238000010923 batch production Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 238000013341 scale-up Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 230000006727 cell loss Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000011143 downstream manufacturing Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000012809 post-inoculation Methods 0.000 description 4
- 230000036515 potency Effects 0.000 description 4
- 230000002028 premature Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 238000011210 chromatographic step Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 238000004114 suspension culture Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 238000001190 Q-PCR Methods 0.000 description 2
- 238000004115 adherent culture Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000010364 biochemical engineering Methods 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 229940112112 capex Drugs 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000000174 oncolytic effect Effects 0.000 description 2
- 238000013386 optimize process Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 241000701242 Adenoviridae Species 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 208000028523 Hereditary Complement Deficiency disease Diseases 0.000 description 1
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102400000368 Surface protein Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 229940021704 adenovirus vaccine Drugs 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940001007 aluminium phosphate Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000001776 amniocyte Anatomy 0.000 description 1
- 239000003011 anion exchange membrane Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 108010067396 dornase alfa Proteins 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000012395 formulation development Methods 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000012007 large scale cell culture Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 238000011140 membrane chromatography Methods 0.000 description 1
- 238000009285 membrane fouling Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000021232 nutrient availability Nutrition 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940107568 pulmozyme Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 239000013017 sartobind Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000002305 strong-anion-exchange chromatography Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960002109 tuberculosis vaccine Drugs 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Sustainable Development (AREA)
- Molecular Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19812208P | 2008-11-03 | 2008-11-03 | |
| EP08168181.9 | 2008-11-03 | ||
| EP08168181 | 2008-11-03 | ||
| US61/198,122 | 2008-11-03 | ||
| PCT/EP2009/064265 WO2010060719A1 (en) | 2008-11-03 | 2009-10-29 | Method for the production of adenoviral vectors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2742474A1 CA2742474A1 (en) | 2010-06-03 |
| CA2742474C true CA2742474C (en) | 2016-05-31 |
Family
ID=40344776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2742474A Active CA2742474C (en) | 2008-11-03 | 2009-10-29 | Method for the production of adenoviral vectors |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10041049B2 (enExample) |
| EP (1) | EP2350268B1 (enExample) |
| JP (1) | JP5770633B2 (enExample) |
| KR (1) | KR101504392B1 (enExample) |
| CN (1) | CN102203242B (enExample) |
| AU (1) | AU2009319254B2 (enExample) |
| BR (1) | BRPI0921651A2 (enExample) |
| CA (1) | CA2742474C (enExample) |
| DK (1) | DK2350268T3 (enExample) |
| EA (1) | EA019928B1 (enExample) |
| ES (1) | ES2532015T3 (enExample) |
| MX (1) | MX2011004292A (enExample) |
| NZ (1) | NZ593235A (enExample) |
| PL (1) | PL2350268T3 (enExample) |
| WO (1) | WO2010060719A1 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2350268T3 (en) | 2008-11-03 | 2015-03-23 | Crucell Holland Bv | PROCEDURE FOR PRODUCING ADENOVIRUS VECTORS |
| AU2010305765B2 (en) | 2009-10-15 | 2015-07-02 | Crucell Holland B.V. | Method for the purification of adenovirus particles |
| WO2011045381A1 (en) | 2009-10-15 | 2011-04-21 | Crucell Holland B.V. | Process for adenovirus purification from high cell density cultures |
| JP5250155B2 (ja) * | 2010-02-15 | 2013-07-31 | クルセル ホランド ベー ヴェー | Ａｄ２６アデノウイルスベクターの製造方法 |
| CA2808556A1 (en) | 2010-09-20 | 2012-03-29 | Crucell Holland B.V. | Therapeutic vaccination against active tuberculosis |
| BR112013004582A2 (pt) | 2010-09-27 | 2016-09-06 | Crucell Holland Bv | método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária |
| CN103347595B (zh) | 2011-02-10 | 2016-01-20 | 克鲁塞尔荷兰公司 | 气动交变压力膜细胞分离系统 |
| WO2013074501A1 (en) | 2011-11-14 | 2013-05-23 | Crucell Holland B.V. | Heterologous prime-boost immunization using measles virus-based vaccines |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| DK2825640T3 (en) | 2012-03-12 | 2016-08-01 | Crucell Holland Bv | BATCHES OF RECOMBINANT ADENOVIRUS WITH CHANGED TERMINAL END |
| US9119813B2 (en) | 2012-03-22 | 2015-09-01 | Crucell Holland B.V. | Vaccine against RSV |
| AU2013237429B2 (en) | 2012-03-22 | 2015-07-23 | Crucell Holland B.V. | Vaccine against RSV |
| SI2988780T1 (sl) | 2013-04-25 | 2019-05-31 | Janssen Vaccines & Prevention B.V. | Stabilizirani topni prefuzijski RSV F polipeptidi |
| CN105408348B (zh) | 2013-06-17 | 2021-07-06 | 扬森疫苗与预防公司 | 稳定化的可溶性融合前rsv f多肽 |
| ES2778928T3 (es) * | 2013-08-30 | 2020-08-12 | Glaxosmithkline Biologicals Sa | Producción a gran escala de virus en cultivos celulares |
| US11008547B2 (en) | 2014-03-25 | 2021-05-18 | Terumo Bct, Inc. | Passive replacement of media |
| BR112017009177A2 (pt) | 2014-11-04 | 2018-12-11 | Janssen Vaccines & Prevention B.V. | vacinas terapêuticas contra hpv16 |
| WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
| EP3319634B1 (en) | 2015-07-07 | 2019-08-21 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
| DK3319633T3 (da) | 2015-07-07 | 2021-02-01 | Janssen Vaccines & Prevention Bv | Vaccine mod rsv |
| US9663766B2 (en) | 2015-07-24 | 2017-05-30 | Bio-Rad Laboratories, Inc. | Methods for purifying adenovirus vectors |
| SG10202001501QA (en) | 2015-08-20 | 2020-04-29 | Janssen Vaccines & Prevention Bv | Therapeutic hpv18 vaccines |
| MA43763B1 (fr) | 2016-04-05 | 2021-03-31 | Janssen Vaccines & Prevention Bv | Protéine f de pré-fusion du vrs soluble et stabilisée pour son utilisation dans la prophylaxie d'une infection vrs |
| MX2018012095A (es) | 2016-04-05 | 2019-01-10 | Janssen Vaccines & Prevention Bv | Vacuna contra vrs. |
| US10358626B2 (en) * | 2016-04-12 | 2019-07-23 | Artemis Biosystems, Inc. | Perfusion filtration systems |
| EP3452087A1 (en) | 2016-05-02 | 2019-03-13 | Janssen Vaccines & Prevention B.V. | Therapeutic hpv vaccine combinations |
| US11965175B2 (en) | 2016-05-25 | 2024-04-23 | Terumo Bct, Inc. | Cell expansion |
| JP2019523644A (ja) | 2016-05-30 | 2019-08-29 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | 安定化された融合前ｒｓｖ ｆタンパク質 |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| JP7229151B2 (ja) | 2016-07-14 | 2023-02-27 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Ｈｐｖワクチン |
| JP7393945B2 (ja) | 2017-03-31 | 2023-12-07 | テルモ ビーシーティー、インコーポレーテッド | 細胞増殖 |
| JP2020519663A (ja) | 2017-05-17 | 2020-07-02 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物 |
| US11229695B2 (en) | 2017-09-15 | 2022-01-25 | Janssen Vaccines & Prevention B.V. | Method for the safe induction of immunity against RSV |
| WO2019086466A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
| SG11202003290RA (en) | 2017-10-31 | 2020-05-28 | Janssen Vaccines & Prevention Bv | Adenovirus and uses thereof |
| AU2018359492B2 (en) | 2017-10-31 | 2023-12-14 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
| SG11202003398SA (en) | 2017-10-31 | 2020-05-28 | Janssen Vaccines & Prevention Bv | Adenovirus vectors and uses thereof |
| TWI827570B (zh) * | 2017-12-11 | 2024-01-01 | 美商安進公司 | 雙特異性抗體產品之連續製造製程 |
| CN110317832B (zh) * | 2018-03-28 | 2022-07-05 | 西比曼生物科技（香港）有限公司 | Gmp级规模化制备重组慢病毒载体的纯化制剂的方法 |
| CN110317791A (zh) | 2018-03-29 | 2019-10-11 | 西比曼生物科技（香港）有限公司 | Gmp级无血清悬浮细胞大规模生产慢病毒的方法 |
| WO2019209632A1 (en) | 2018-04-24 | 2019-10-31 | Merck Sharp & Dohme Corp. | Scalable chromatography process for purification of human cytomegalovirus |
| CR20210306A (es) | 2018-11-13 | 2021-07-22 | Janssen Vaccines & Prevention Bv | Proteínas f de prefusión del vrs estabilizadas |
| MX2022000002A (es) * | 2019-07-01 | 2022-03-17 | Ology Bioservices Inc | Método para cultivo de células adherentes en un biorreactor multiparalelo. |
| EP4097122A4 (en) | 2020-01-31 | 2024-07-17 | Beth Israel Deaconess Medical Center, Inc. | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUS INFECTION - SARS-COV-2 VACCINES |
| GB202013940D0 (en) | 2020-09-04 | 2020-10-21 | Synpromics Ltd | Regulatory nucleic acid sequences |
| AU2021358957A1 (en) | 2020-10-07 | 2023-06-08 | AskBio Inc. | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 |
| AU2022249741A1 (en) | 2021-04-01 | 2023-09-21 | Msd International Business Gmbh | Stabilized pre-fusion piv3 f proteins |
| WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023110618A1 (en) | 2021-12-16 | 2023-06-22 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
| EP4590689A1 (en) | 2022-09-23 | 2025-07-30 | Janssen Vaccines & Prevention B.V. | Stabilized trimeric class i fusion proteins |
| EP4590690A1 (en) | 2022-09-23 | 2025-07-30 | Janssen Vaccines & Prevention B.V. | Pre-fusion human piv1 f proteins |
| CN120344553A (zh) | 2022-10-06 | 2025-07-18 | Msd国际商务股份有限公司 | 稳定的融合前piv3 f蛋白 |
| WO2024190895A1 (ja) | 2023-03-15 | 2024-09-19 | 東レ株式会社 | フィルターユニット、精製装置及び精製液の製造方法 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04241381A (ja) | 1991-01-16 | 1992-08-28 | Brother Ind Ltd | 電子学習機 |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
| JP3816518B2 (ja) | 1994-06-10 | 2006-08-30 | ジェンベク、インコーポレイティッド | 相補的なアデノウイルスベクター系と細胞系 |
| US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
| US5770442A (en) | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
| US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
| US5994128A (en) | 1995-06-15 | 1999-11-30 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| JPH11511326A (ja) | 1995-08-30 | 1999-10-05 | ジエンザイム コーポレイション | アデノウィルスおよびａａｖの精製 |
| US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
| US5891690A (en) | 1996-04-26 | 1999-04-06 | Massie; Bernard | Adenovirus E1-complementing cell lines |
| US6485958B2 (en) | 1996-07-01 | 2002-11-26 | Gencell Sa | Method for producing recombinant adenovirus |
| FR2751343B1 (fr) | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
| WO1998022588A2 (en) | 1996-11-20 | 1998-05-28 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
| US7732129B1 (en) * | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| US6261823B1 (en) | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
| JP2000509614A (ja) | 1997-03-04 | 2000-08-02 | バクスター インターナショナル インコーポレイテッド | アデノウイルスｅ１−相補性細胞系 |
| US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
| US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
| PL197747B1 (pl) | 1998-02-17 | 2008-04-30 | Schering Corp | Kompozycja zawierająca adenowirusa, sposoby zatężania preparatu wirusa oraz sposób oczyszczania preparatu wirusa |
| US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
| BR9909789A (pt) | 1998-04-22 | 2000-12-26 | Genvec Inc | Método de purificação eficiente de adenovìrus |
| US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
| US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
| US20040043489A1 (en) | 1998-07-08 | 2004-03-04 | Menzo Havenga | Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use |
| DK1133316T3 (da) | 1998-11-16 | 2009-05-25 | Introgen Therapeutics Inc | Adenovirus-formulering til genterapi |
| CA2356373A1 (fr) | 1998-12-31 | 2000-07-13 | Aventis Pharma S.A. | Methode de separation de particules virales |
| AU774437B2 (en) | 1999-02-22 | 2004-06-24 | Transgene S.A. | Method for obtaining a purified viral preparation |
| ES2289426T3 (es) | 1999-05-17 | 2008-02-01 | Crucell Holland B.V. | Adenovirus recombinante humano de serotipo 35. |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| US20050232900A1 (en) | 1999-05-18 | 2005-10-20 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| DE19955558C2 (de) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
| US6544424B1 (en) | 1999-12-03 | 2003-04-08 | Refined Technology Company | Fluid filtration system |
| WO2001066137A1 (en) | 2000-03-07 | 2001-09-13 | Merck & Co., Inc. | Adenovirus formulations |
| US7235233B2 (en) | 2000-09-26 | 2007-06-26 | Crucell Holland B.V. | Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts |
| US20020064860A1 (en) | 2000-11-29 | 2002-05-30 | Schering Corporation | Method for purifying adenoviruses |
| CA2469491A1 (en) | 2001-12-12 | 2003-06-19 | Kerrie Setiawan | Composition for viral preservation |
| JP4488290B2 (ja) | 2002-01-24 | 2010-06-23 | ザ・スクリップス・リサーチ・インスティテュート | 効率的ターゲティングのためのファイバーシャフト変異 |
| US20030180936A1 (en) | 2002-03-15 | 2003-09-25 | Memarzadeh Bahram Eric | Method for the purification, production and formulation of oncolytic adenoviruses |
| WO2004001032A2 (en) | 2002-04-25 | 2003-12-31 | Crucell Holland B.V. | Stable adenoviral vectors and methods for propagation thereof |
| KR101021387B1 (ko) | 2002-04-25 | 2011-03-14 | 크루셀 홀란드 비.브이. | 아데노바이러스 벡터를 생산하기 위한 수단 및 방법 |
| ATE494362T1 (de) | 2002-05-14 | 2011-01-15 | Merck Sharp & Dohme | Verfahren zur reinigung von adenovirus |
| AU2003288273A1 (en) | 2002-10-23 | 2004-05-13 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
| US20080153083A1 (en) | 2003-10-23 | 2008-06-26 | Crucell Holland B.V. | Settings for recombinant adenoviral-based vaccines |
| CA2507915C (en) | 2002-12-17 | 2013-07-02 | Crucell Holland B.V. | Recombinant viral-based malaria vaccines |
| JP2007525166A (ja) | 2003-03-28 | 2007-09-06 | ザ・スクリップス・リサーチ・インスティテュート | 樹状細胞に対する感染性が増大したアデノウイルス粒子と、肝細胞に対する感染性が低下した粒子 |
| WO2005033320A1 (en) | 2003-10-02 | 2005-04-14 | Crucell Holland B.V. | Packaging cells for recombinant adenovirus |
| CA2555412C (en) | 2004-02-23 | 2013-06-25 | Crucell Holland B.V. | Virus purification methods |
| ES2456015T3 (es) * | 2004-03-05 | 2014-04-21 | Dsm Ip Assets B.V. | Procedimiento para cultivar células mediante perfusión continua y flujo tangencial alternante |
| US7629167B2 (en) | 2004-06-04 | 2009-12-08 | Xcellerex, Inc. | Disposable bioreactor systems and methods |
| KR101253363B1 (ko) | 2004-10-13 | 2013-04-15 | 베쓰 이스라엘 디코니스 메디칼 센터 인크 | 개선된 아데노바이러스 벡터 및 그것의 용도 |
| SI1802336T1 (sl) | 2004-10-14 | 2012-01-31 | Crucell Holland Bv | Začetna/obnovitvena cepiva proti malariji |
| EA012037B1 (ru) | 2004-11-16 | 2009-06-30 | Круселл Холланд Б.В. | Поливалентные вакцины, содержащие рекомбинантные вирусные векторы |
| EP1851343A2 (en) | 2005-02-11 | 2007-11-07 | Merck and Co., Inc. | Adenovirus serotype 26 vectors, nucleic acid and viruses produced thereby |
| EP1869171B2 (en) | 2005-04-11 | 2015-10-14 | Crucell Holland B.V. | Virus purification using ultrafiltration |
| JP2008541730A (ja) | 2005-05-23 | 2008-11-27 | ヴァクシン インコーポレイテッド | 高力価かつ複製コンピテントアデノウイルス不含である組換えアデノウイルスベクターの迅速な作成法 |
| WO2007010409A2 (en) | 2005-07-22 | 2007-01-25 | Pergo (Europe) Ab | Flooring system including a preglue |
| KR101345936B1 (ko) | 2005-08-15 | 2013-12-31 | 박신 인크. | 비복제성 벡터화된 백신 투여에 의한 조류 면역화 |
| WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
| US20090110695A1 (en) | 2006-03-27 | 2009-04-30 | Menzo Jans Emko Havenga | Compositions Comprising a Recombinant Adenovirus and an Adjuvant |
| EA200900032A1 (ru) | 2006-07-18 | 2011-02-28 | Глаксосмитклайн Байолоджикалс С.А. | Вакцины против малярии |
| ES2609418T3 (es) | 2007-03-02 | 2017-04-20 | Glaxosmithkline Biologicals Sa | Procedimiento novedoso y composiciones |
| US9109193B2 (en) | 2007-07-30 | 2015-08-18 | Ge Healthcare Bio-Sciences Corp. | Continuous perfusion bioreactor system |
| CN101855371A (zh) | 2007-11-14 | 2010-10-06 | 张惇杰 | 制备用于锂离子电池应用的空气敏感性电极材料的方法和装置 |
| WO2009117134A2 (en) | 2008-03-21 | 2009-09-24 | National Institutes Of Health | Aerosolized genetic vaccines and methods of use |
| DK2350268T3 (en) | 2008-11-03 | 2015-03-23 | Crucell Holland Bv | PROCEDURE FOR PRODUCING ADENOVIRUS VECTORS |
| KR101548790B1 (ko) | 2009-07-16 | 2015-08-31 | 크루셀 홀란드 비.브이. | 백신 제조를 위한 고역가 폴리오바이러스의 제조 |
| WO2011045381A1 (en) | 2009-10-15 | 2011-04-21 | Crucell Holland B.V. | Process for adenovirus purification from high cell density cultures |
| US20120315696A1 (en) | 2010-02-15 | 2012-12-13 | Alfred Luitjens | METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS |
| JP5250155B2 (ja) | 2010-02-15 | 2013-07-31 | クルセル ホランド ベー ヴェー | Ａｄ２６アデノウイルスベクターの製造方法 |
-
2009
- 2009-10-29 DK DK09744140.6T patent/DK2350268T3/en active
- 2009-10-29 JP JP2011533718A patent/JP5770633B2/ja not_active Expired - Fee Related
- 2009-10-29 WO PCT/EP2009/064265 patent/WO2010060719A1/en not_active Ceased
- 2009-10-29 PL PL09744140T patent/PL2350268T3/pl unknown
- 2009-10-29 US US13/126,978 patent/US10041049B2/en active Active
- 2009-10-29 AU AU2009319254A patent/AU2009319254B2/en not_active Ceased
- 2009-10-29 CA CA2742474A patent/CA2742474C/en active Active
- 2009-10-29 NZ NZ593235A patent/NZ593235A/xx not_active IP Right Cessation
- 2009-10-29 BR BRPI0921651-0A patent/BRPI0921651A2/pt not_active Application Discontinuation
- 2009-10-29 EA EA201170638A patent/EA019928B1/ru not_active IP Right Cessation
- 2009-10-29 ES ES09744140.6T patent/ES2532015T3/es active Active
- 2009-10-29 EP EP09744140.6A patent/EP2350268B1/en active Active
- 2009-10-29 CN CN2009801438951A patent/CN102203242B/zh not_active Expired - Fee Related
- 2009-10-29 KR KR1020117010793A patent/KR101504392B1/ko not_active Expired - Fee Related
- 2009-10-29 MX MX2011004292A patent/MX2011004292A/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP2350268A1 (en) | 2011-08-03 |
| CN102203242B (zh) | 2013-06-12 |
| WO2010060719A1 (en) | 2010-06-03 |
| US20110207202A1 (en) | 2011-08-25 |
| ES2532015T3 (es) | 2015-03-23 |
| CA2742474A1 (en) | 2010-06-03 |
| PL2350268T3 (pl) | 2015-05-29 |
| EA019928B1 (ru) | 2014-07-30 |
| KR20110093793A (ko) | 2011-08-18 |
| DK2350268T3 (en) | 2015-03-23 |
| KR101504392B1 (ko) | 2015-03-19 |
| AU2009319254B2 (en) | 2015-04-30 |
| JP5770633B2 (ja) | 2015-08-26 |
| MX2011004292A (es) | 2011-05-31 |
| BRPI0921651A2 (pt) | 2015-08-18 |
| EP2350268B1 (en) | 2014-12-24 |
| JP2012507270A (ja) | 2012-03-29 |
| AU2009319254A1 (en) | 2010-06-03 |
| EA201170638A1 (ru) | 2011-12-30 |
| CN102203242A (zh) | 2011-09-28 |
| HK1160664A1 (en) | 2012-08-10 |
| US10041049B2 (en) | 2018-08-07 |
| NZ593235A (en) | 2013-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2742474C (en) | Method for the production of adenoviral vectors | |
| CA2786835C (en) | Method for the production of ad26 adenoviral vectors | |
| US20180080010A1 (en) | Method for the production of ad26 adenoviral vectors | |
| US8124106B2 (en) | Virus purification methods | |
| US8574595B2 (en) | Virus purification using ultrafiltration | |
| HK1160664B (en) | Method for the production of adenoviral vectors | |
| HK1180008B (en) | Method for the production of ad26 adenoviral vectors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140610 |